organization
US Food and Drug Administration (FDA): role, centres and 2026 changes
Also known as FDA, Food and Drug Administration, U.S. FDA
The US Food and Drug Administration is the agency within the Department of Health and Human Services that regulates drugs, vaccines and other biologics, medical devices, most of the food supply, cosmetics and tobacco.[1][2][3][4] It oversees more than $4.1 trillion worth of products, and its roughly $7 billion budget is split almost evenly between Congress and industry user fees.[5][6] The agency lost about 3,500 jobs in 2025 cuts, and after Commissioner Marty Makary's departure was announced in May 2026, an acting commissioner was named; one was still in place in October 2026.[7][8][9]
Key facts
This page describes the agency and its processes. It is not medical advice: questions about a specific medicine, device or recall are for a clinician or pharmacist.
The US Food and Drug Administration (FDA) is a federal regulator within the Department of Health and Human Services (HHS).[1] It is responsible for the safety, efficacy and security of human and veterinary drugs, biological products and medical devices, and for the safety of the food supply, cosmetics and radiation-emitting products.[2] It also regulates how tobacco products are made, marketed and distributed.[4] The agency’s roots go back to the Food and Drugs Act, signed on 30 June 1906. That law policed labelling rather than requiring approval before sale.[10]
Scale and funding
FDA’s January 2026 fact sheet says the agency oversees more than $4.1 trillion worth of food, tobacco and medical products. Those products make up about 21 cents of every dollar US consumers spend.[5] It counts more than 24,000 approved prescription drug products, more than 130,000 medical device products and about 804 licensed biologics, and it regulates about 77% of the US food supply.[3] Much of the supply chain is abroad. About 78% of manufacturers of active pharmaceutical ingredients are outside the US, and more than half of nearly 300,000 registered facilities are overseas.[11]
The fiscal 2025 budget was about $7 billion. Congress provided 51% ($3.6 billion) and industry user fees 49% ($3.5 billion), and the budget covered 20,593 full-time equivalent staff.[6]
Centres and what they do
FDA is organised into product centres plus the Office of the Commissioner, an inspections office and an Oncology Center of Excellence.[12]
| Centre | Remit |
|---|---|
| CDER (drugs) | Prescription and over-the-counter drugs, including biological therapeutics and generics; sunscreens and fluoride toothpaste also count as drugs[13] |
| CBER (biologics) | Biological products for human use, under the Public Health Service Act and the Food, Drug and Cosmetic Act[14] |
| CDRH (devices) | Safe, effective medical devices and safe radiation-emitting products[15] |
| Other centres | Human Foods Program, tobacco products, veterinary medicine[12] |
CBER’s work includes the annual flu vaccine update. After FDA’s vaccine advisory committee meets, CBER advises manufacturers on which strains to use.[16]
Approvals, recalls and advisory committees
Approvals. A drug reaches FDA only after clinical trials, described in how clinical trials work. The sponsor then files a New Drug Application with all data from preclinical work to Phase 3. Once the application is accepted as complete, the review team has 6 to 10 months to decide.[17] Dietary supplements are different: FDA has no authority to approve them before they are sold.[18]
Recalls. A recall can be started by the company, at FDA’s request or by FDA order. FDA then classifies it by hazard, and Class I means a reasonable probability of serious harm or death.[19][20] The process is explained in fda-recall-process, with recent cases in the eye drop recalls tracker.[21]
Advisory committees. FDA uses committees and panels to get independent expert advice on scientific, technical and policy matters.[22] Meetings must be announced in the Federal Register at least 15 calendar days ahead, and members of the public can register to speak.[23] On 12 March 2026, for example, the vaccine committee (VRBPAC) voted 7-0 for the WHO-recommended flu strains for the 2026-27 US season.[24]
Changes in 2025 and 2026
Job cuts. FDA lost about 3,500 jobs in the HHS workforce cuts announced in March 2025, NPR and NOTUS reported.[7]
Vaccine policy. In August 2025 FDA limited Pfizer-BioNTech’s COVID-19 vaccine Comirnaty to people 65 and older and younger people at high risk of severe disease.[25] Under the framework behind that decision, approval for healthy people requires randomised trials that measure clinical outcomes.[26] The wider debate is covered in the US mRNA vaccine policy debate.[25]
Leadership. On 12 May 2026 President Trump said Commissioner Marty Makary was leaving and that Deputy Commissioner for Food Kyle Diamantas would lead the agency in an acting capacity.[8] Reuters and the Regulatory Affairs Professionals Society reported that Makary had faced criticism and conflicts over flavoured vaping products, abortion-pill policy and the agency’s oversight of medical products.[27] An FDA press release on 14 October 2026 still named Diamantas as acting commissioner.[9]
This page will be updated when a permanent commissioner is nominated or confirmed.
Read next
Next in the crash course
CDC: disease surveillance, vaccine advice and 2025-26 changes
What the US Centers for Disease Control and Prevention does: disease surveillance, ACIP vaccine recommendations, and its 2025-26 leadership and ACIP changes.
Questions readers ask
What does the FDA regulate?
Human and veterinary drugs, biological products such as vaccines, medical devices, the safety of the food supply, cosmetics, radiation-emitting products and tobacco. FDA says it regulates about 77% of the US food supply.[2][4][3]
What is the difference between CDER, CBER and CDRH?
CDER regulates prescription and over-the-counter drugs, including generics. CBER regulates biological products for human use. CDRH oversees medical devices and radiation-emitting products.[13][14][15]
How long does FDA take to review a new drug?
Once FDA accepts a New Drug Application as complete, its review team has 6 to 10 months to decide whether to approve the drug.[17]
Who pays for the FDA?
Of FDA's roughly $7 billion fiscal 2025 budget, 51% ($3.6 billion) came from congressional budget authority and 49% ($3.5 billion) from industry user fees.[6]
Sources
· 28 claims from 9 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
FDA is a federal regulatory agency within the US Department of Health and Human Services. confirmedas of 2026-11-07
- FDA Organization · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [2]
FDA is responsible for protecting public health by ensuring the safety, efficacy and security of human and veterinary drugs, biological products and medical devices, and the safety of the food supply, cosmetics and radiation-emitting products. confirmedas of 2026-11-07
- What We Do · US Food and Drug Administration · Primary source · FDA Mission (retrieved 2026-11-07)
- [3]
FDA's January 2026 figures count more than 24,000 approved prescription drug products, more than 130,000 medical device products and about 804 licensed biologics, and say FDA regulates about 77% of the US food supply. confirmedas of 2026-01-28
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 1 (retrieved 2026-11-07)
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 1 (retrieved 2026-11-07)
- [4]
FDA also regulates the manufacturing, marketing and distribution of tobacco products. confirmedas of 2026-11-07
- What We Do · US Food and Drug Administration · Primary source · FDA Mission (retrieved 2026-11-07)
- [5]
FDA's January 2026 "FDA at a Glance" says the agency oversees more than $4.1 trillion worth of food, tobacco and medical products, and that FDA-regulated products account for about 21 cents of every dollar US consumers spend. confirmedas of 2026-01-28
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 1, FDA Regulated Products and Facilities (retrieved 2026-11-07)
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 1 (retrieved 2026-11-07)
- [6]
FDA's fiscal year 2025 budget was about $7 billion, of which 51% ($3.6 billion) came from congressional budget authority and 49% ($3.5 billion) from industry user fees, covering 20,593 full-time equivalent staff. confirmedas of 2026-01-28
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 2, FY2025 budget (retrieved 2026-11-07)
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 2, FY2025 budget (retrieved 2026-11-07)
- [7]
The FDA lost about 3,500 jobs in the 2025 Department of Health and Human Services workforce cuts announced in March 2025. confirmedas of 2026-07-28
- The FDA will lose 3,500 jobs as part of the HHS cuts. How will this impact you? · NPR (via VPM) · Secondary source · 2025-03-30 (retrieved 2026-11-07)
- The FDA Is Officially Codifying DOGE-Era Changes · NOTUS · Secondary source · 2026-07-28 (retrieved 2026-11-07)
- [8]
On 12 May 2026 President Trump said FDA Commissioner Marty Makary was leaving the agency and that Deputy Commissioner for Food Kyle Diamantas would lead it in an acting capacity. confirmedas of 2026-05-12
- Trump says FDA Commissioner Makary is out · Reuters (via The Spokesman-Review) · Secondary source · 2026-05-12 (retrieved 2026-11-07)
- Trump confirms Makary is out at FDA · Regulatory Affairs Professionals Society (Regulatory Focus) · Secondary source · 2026-05-12 (retrieved 2026-11-07)
- [9]
As of an FDA press release dated 14 October 2026, Kyle Diamantas was serving as acting FDA commissioner. confirmedas of 2026-10-14
- FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development · US Food and Drug Administration · Primary source · 2026-10-14 (retrieved 2026-11-07)
- [10]
President Theodore Roosevelt signed the Food and Drugs Act, known as the Wiley Act, on 30 June 1906; it regulated product labelling rather than requiring pre-market approval. confirmedas of 2026-11-07
- Part I: The 1906 Food and Drugs Act and Its Enforcement · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- Part I: The 1906 Food and Drugs Act and Its Enforcement · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [11]
FDA says about 78% of manufacturers of active pharmaceutical ingredients are outside the US, and that FDA-regulated products are made or handled at nearly 300,000 registered facilities, more than half of them abroad. confirmedas of 2026-01-28
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 1 (retrieved 2026-11-07)
- FDA at a Glance, January 2026 · US Food and Drug Administration, Office of the Commissioner · Primary source · 2026-01-28 · Page 1 (retrieved 2026-11-07)
- [12]
FDA's organisation includes the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER), the Human Foods Program, the Center for Tobacco Products, the Center for Veterinary Medicine, the Office of Inspections and Investigations and the Oncology Center of Excellence. confirmedas of 2026-11-07
- FDA Organization · US Food and Drug Administration · Primary source · Section navigation (retrieved 2026-11-07)
- [13]
CDER regulates prescription and over-the-counter drugs, including biological therapeutics and generic drugs; products such as fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens also count as drugs. confirmedas of 2026-11-07
- Center for Drug Evaluation and Research (CDER) · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- Center for Drug Evaluation and Research (CDER) · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [14]
CBER is the FDA centre that regulates biological products for human use, such as vaccines, under the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. confirmedas of 2026-11-07
- Center for Biologics Evaluation and Research (CBER) · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [15]
CDRH is responsible for assuring that medical devices are safe, effective and high quality and that radiation-emitting products are safe. confirmedas of 2026-11-07
- Center for Devices and Radiological Health · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [16]
In the US, after VRBPAC's recommendations, FDA's Center for Biologics Evaluation and Research advises manufacturers on strain composition, and makers update their licensed vaccines through strain change supplements. confirmedas of 2026-03-10
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · Regulatory Pathway, p. 4 (retrieved 2026-11-07)
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · Regulatory Pathway, p. 4 (retrieved 2026-11-07)
- [17]
To market a new drug, a developer files a New Drug Application containing everything from preclinical data to Phase 3 results; once FDA accepts the application as complete, its review team has 6 to 10 months to decide whether to approve. confirmedas of 2026-11-07
- Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · New Drug Application (retrieved 2026-11-07)
- Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · FDA Review (retrieved 2026-11-07)
- [18]
Under the Dietary Supplement Health and Education Act, FDA does not have the authority to approve dietary supplements before they are marketed. confirmedas of 2026-10-11
- Questions and Answers on Dietary Supplements · US Food and Drug Administration · Primary source (retrieved 2026-10-11)
- [19]
FDA describes a recall as a firm's action to remove a product from the market, conducted on the firm's own initiative, at FDA's request, or by FDA order under statutory authority. confirmedas of 2026-10-11
- Recalls Background and Definitions · US Food and Drug Administration · Primary source (retrieved 2026-10-11)
- [20]
A Class I recall is a situation where there is a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death. confirmedas of 2026-10-11
- Recalls Background and Definitions · US Food and Drug Administration · Primary source (retrieved 2026-10-11)
- [21]
The FDA Enforcement Report lists all recalls monitored by FDA once they are classified, and recall classifications are usually set after the firm supplies the information FDA needs to assess the risk. confirmedas of 2026-10-11
- Enforcement Reports · US Food and Drug Administration · Primary source (retrieved 2026-10-11)
- [22]
FDA uses advisory committees and panels to obtain independent expert advice on scientific, technical and policy matters. confirmedas of 2026-11-07
- Advisory Committees · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [23]
FDA must announce advisory committee meetings in the Federal Register at least 15 calendar days in advance, and members of the public can register to speak in an open public hearing. confirmedas of 2026-11-07
- Common Questions and Answers about FDA Advisory Committee Meetings · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- Common Questions and Answers about FDA Advisory Committee Meetings · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
- [24]
On 12 March 2026 the FDA's VRBPAC voted 7-0 for the WHO-recommended egg-based strains and 7-0 for the cell- and recombinant-based strains for US 2026-27 vaccines. confirmedas of 2026-03-12
- Summary minutes, 191st Vaccines and Related Biological Products Advisory Committee meeting, March 12, 2026 · US Food and Drug Administration · Primary source · Voting Questions 1 and 2 (retrieved 2026-11-07)
- FDA vaccine advisers recommend adding subclade K to fall shots · CIDRAP (University of Minnesota) · Secondary source · 2026-03-12 (retrieved 2026-11-07)
- Summary minutes, 191st Vaccines and Related Biological Products Advisory Committee meeting, March 12, 2026 · US Food and Drug Administration · Primary source · Voting questions (PDF) (retrieved 2026-11-07)
- [25]
In August 2025 the FDA limited the approved use of Pfizer-BioNTech's Comirnaty to people 65 and older and younger people with at least one condition that puts them at high risk of severe COVID-19. confirmedas of 2025-08-25
- CBER Center Director Decisional Memo: COMIRNATY sBLA (August 25, 2025) · US Food and Drug Administration · Primary source · 2025-08-25 (retrieved 2026-10-10)
- FDA Approves COVID-19 Vaccines With Postmarketing Study Strings Attached · Managed Healthcare Executive · Secondary source · 2025-08-27 (retrieved 2026-10-10)
- [26]
Under the FDA framework, approval for healthy people requires randomized trials measuring clinical outcomes; Pfizer-BioNTech agreed to a saline placebo-controlled trial in healthy adults aged 50-64. confirmedas of 2025-08-25
- CBER Center Director Decisional Memo: COMIRNATY sBLA (August 25, 2025) · US Food and Drug Administration · Primary source · 2025-08-25 (retrieved 2026-10-10)
- FDA Approves COVID-19 Vaccines With Postmarketing Study Strings Attached · Managed Healthcare Executive · Secondary source · 2025-08-27 (retrieved 2026-10-10)
- [27]
Reuters and RAPS reported that Makary had faced criticism and conflicts over flavoured vaping products, abortion-pill policy and the agency's oversight of medical products. confirmedas of 2026-05-12
- Trump says FDA Commissioner Makary is out · Reuters (via The Spokesman-Review) · Secondary source · 2026-05-12 (retrieved 2026-11-07)
- Trump confirms Makary is out at FDA · Regulatory Affairs Professionals Society (Regulatory Focus) · Secondary source · 2026-05-12 (retrieved 2026-11-07)
- [28]
The Advisory Committee on Immunization Practices (ACIP) is a federal advisory committee of medical and public health experts that develops recommendations on vaccine use, and CDC sets the US adult and childhood immunisation schedules based on its recommendations. confirmedas of 2025-08-12
- About ACIP · Centers for Disease Control and Prevention · Primary source · 2025-08-12 · Read through WebFetch (cdc.gov blocks curl) (retrieved 2026-11-07)
- About ACIP · Centers for Disease Control and Prevention · Primary source · 2025-08-12 · Read through WebFetch (cdc.gov blocks curl) (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.
Cite this page
"US Food and Drug Administration (FDA): role, centres and 2026 changes." ContentLora, updated Nov 7, 2026. https://contentlora.com/wiki/us-food-and-drug-administration
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.